伊卡林通过降低阴茎洞腔组织中的GRK2的调节来改善自发高血压大鼠的勃起功能
Yanke Li1, Jun Jiang2, Rui Jiang1
1Department of Urology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, China.
The journal of sexual medicine
|February 5, 2025
概括
伊卡林通过减少GRK2表达来改善高血压大鼠的勃起功能障碍 (ED). 这增强了AKT/eNOS/NO通路,降低了氧化应激和亡,以改善勃起功能.
科学领域:
- 生物医学研究的研究.
- 药理学 药理学是指药理学的学科.
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
背景情况:
- 高血压是勃起功能障碍 (ED) 的重要危险因素.
- 伊卡林在自发高血压大鼠 (SHRs) 中显示出改善勃起功能的潜力.
- 通过其在eNOS酸化中的作用,GRK2与内皮功能障碍有关.
研究的目的:
- 调查伊卡林是否可以改善SHRs中的勃起功能.
- 为了确定伊卡林是否调节阴茎洞穴组织中的GRK2表达.
- 阐明涉及AKT/eNOS/NO通路的潜在分子机制.
主要方法:
- SHR和WKY大鼠被用或不使用伊卡林 (10毫克/公斤/天) 治疗了4周.
- 测量包括洞穴内压力/平均动脉压 (ICPmax/MAP),血清,以及GRK2,p-AKT/AKT,p-eNOS/eNOS,caspase-3,氧化物 (NO),超氧化物失调酶 (SOD) 和甲基 (MDA) 的水平.
- 评估了蛋白质相互作用 (GRK2-AKT) 和亡率.
主要成果:
- 与WKY大鼠相比,SHRs表现出更高的GRK2表达,抑制了AKT/eNOS/NO信号传递,增加了氧化应激,以及勃起功能受损.
- 在SHR中,伊卡林治疗显著降低了GRK2和caspase-3水平,降低了GRK2-AKT相互作用,降低了MDA和亡率.
- 伊卡林治疗上调了p-AKT,p-eNOS,NO和SOD水平,改善了SHR中的ICPmax/MAP比率.
结论:
- 伊卡林有效地改善了SHRs的勃起功能,可能是通过降低阴茎洞穴组织中GRK2表达的调节.
- 该机制涉及AKT/eNOS/NO通路的上调,氧化应激的减少和亡的减少.
- 需要进行进一步的研究,以充分阐明伊卡林降低GRK2的特定途径.
相关概念视频
01:25Antihypertensive Drugs: Direct Renin Inhibitors
477
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
477
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
462
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
462
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
574
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
574
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
375
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
375
01:23Antihypertensive Drugs: Vasodilators
463
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
463
01:31Adrenergic Receptors: ɑ Subtype
1.4K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
1.4K